記住我
Topic: Gastrointestinal cancer
Category: Original article
Patients and Methods: The study was conducted at the Regional Cancer Centre (RCC), Sher-i-Kashmir Institute of Medical Sciences (SKIMS), Soura, Srinagar, J&K, India for a period of 7 months. A total of 251 patients were included in this retrospective study, of which 177 (Group I) had been treated with a combination of Carboplatin and Paclitaxel while 74 patients (Group II) had been treated with 5-FU and Cisplatin combination.
Results: The median overall survival (OS) was 20.7 months for patients in Group I and 17.1 months for patients in Group II (HR: 1.200; 95% Confidence Interval [CI], p=0.176). The median progression-free survival (PFS) was 12.26 months for subjects of Group I and 12.33 months for Group II subjects (HR: 0.609; 95% CI; p=0.909). Haematological toxicity (≥ grade III) in terms of anaemia, leukocytopenia and thrombocytopenia in Carboplatin and Paclitaxel group (1.7%, 8%, and 18%) was significantly higher than in the 5-FU and Cisplatin group (1.36%, 0%, and 38%) (95% CI; p<0.05). Among non-haematological toxicities, bradycardia was the most notable side-effect of 5-FU and Cisplatin group (18.9%) followed by diarrhoea/vomiting (6.75%) and cough (2.7%). The major side-effect seen in patients treated with of Carboplatin and Paclitaxel combination group was diarrhoea/vomiting (4.52%), followed by mucositis (3.39%) and cough (2.25%) (95% CI; p<0.05).
Conclusions: Results suggest that Carboplatin and Paclitaxel regimen is the preferred regimen for patients with potentially curable EC and has higher patient compliance compared to 5-FU and Cisplatin regimen. Toxicity, excluding haematological events, occurred less frequently in the group that received Carboplatin and Paclitaxel compared to toxicity rates in patients who received 5-FU and Cisplatin regimen.
To cite this article Nisar N., Maqbool Lone M. Department of Radiation Oncology, Sher-i-Kashmir Institute of Medical Sciences, Department of Radiation Oncology, Sher-i-Kashmir Institute of Medical Sciences, Srinagar, J&K, India, India , Tabassum N. Department of Pharmaceutical Sciences, University of Kashmir, Hazratbal Srinagar, India Comparison of survival and adverse effect profile in patients with esophageal cancer treated with the combination of carboplatin and paclitaxel vs. 5-flourouracil and cisplatin WCRJ 2022;
9: e2399
DOI: 10.32113/wcrj_20229_2399
Submission date: 13 Jun 2022
Revised on: 20 Jul 2022
Accepted on: 09 Sep 2022
Published online: 15 Sep 2022
留言 (0)